- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
B+L introduces new innovations, products
Bausch + Lomb presented several product innovations in pharmaceuticals, OTC offerings, IOLs, and surgical devices and equipment during the annual meeting of the American Academy of Ophthalmology.
Bridgewater, NJ-Bausch + Lomb presented several product innovations in pharmaceuticals, OTC offerings, IOLs, and surgical devices and equipment during the annual meeting of the American Academy of Ophthalmology.
Highlights include the Trulign Toric IOL, which is now available in an expanded power range.
Since its approval by the FDA in May 2013, the toric IOL has been available in mid-range powers between 17 and 25 D. The expansion now includes 10 to 16.5 (in half diopter steps) making the toric IOL available to cataract patients throughout the most popular power range, according to the company.
Additional powers from 25.5 to 33 D are expected later this fall.
Additionally, Bausch + Lomb’s ZeroPhaco I/A handpiece was introduced for femtocataract surgery.
The disposable handpiece is designed for the removal of soft cataracts following femtosecond laser fragmentation without the use of ultrasonic energy.
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.
